biote (NASDAQ:BTMD) Releases Earnings Results, Beats Estimates By $0.01 EPS

biote (NASDAQ:BTMD) posted its quarterly earnings results on Wednesday. The company reported $0.10 EPS for the quarter, beating the consensus estimate of $0.09 by $0.01, Zacks reports. biote had a net margin of 5.20% and a negative return on equity of 32.41%. biote updated its FY 2025 guidance to EPS.

biote Stock Down 0.7 %

BTMD stock traded down $0.03 during mid-day trading on Wednesday, reaching $4.10. The company had a trading volume of 289,898 shares, compared to its average volume of 139,587. biote has a one year low of $4.03 and a one year high of $8.44. The stock has a market capitalization of $222.78 million, a P/E ratio of 15.77 and a beta of 1.07. The stock’s 50-day simple moving average is $5.11 and its two-hundred day simple moving average is $5.60.

Analysts Set New Price Targets

Separately, Craig Hallum initiated coverage on biote in a research note on Monday, December 16th. They issued a “buy” rating and a $12.00 target price for the company.

About biote

biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support.